ABT's Structural Heart, Rhythm Management and Neuromodulation businesses are likely to have driven its first-quarter 2025 performance.
Investors looking to maintain exposure to healthcare can invest in large-cap U.S.-based companies like UHS, BMRN and ABT.
Abbott (ABT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Five defensive stocks to buy at this soaring volatility are TAP, CNP, WEC, BSX, HCA.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Investors feel optimistic about Abbott's robust strength in the EPD, Diabetes and Nutrition businesses. However, unfavorable forex impacts are concerning.
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Abbott achieves early CE Mark approval for the Volt PFA system.
Abbott presents positive TRILUMINATE Pivotal trial data, which demonstrates TriClip system's safety and effectiveness at the ACC.25.
In the latest trading session, Abbott (ABT) closed at $132.65, marking a +1.4% move from the previous day.
Abbott Laboratories (ABT 4.02%) stock was in fine health on the second-to-last trading day of the week, thanks to news from Europe. Investors greeted this positively, rewarding the company with a share price gain on the day that approached 4%.